TOXICO-ALLERGIC CONJUNCTIVITIS IN PATIENTS WITH PRIMARY GLAUCOMA AGAINST THE BACKGROUND OF ANTIHYPERTENSIVE TREATMENT
- Autores: Yani E.V1, Seliverstova K.E1
-
Afiliações:
- FSBI "Moscow Scientific Research Institute of Eye Diseases n.a. Helmholtz "
- Edição: Nº 20 (2016)
- Páginas: 12-14
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/289558
- ID: 289558
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Glaucoma is a leading cause of visual impairment and blindness worldwide. Despite the success of laser and surgical therapies, administration of medications in the form of eye drops remains the standard approach to the therapy of glaucoma. The study was aimed to the evaluation of the impact of modern ocular hypotensive medications on the development of drug-induced allergy. Manifestations of ocular surface disease may be associated with the influence of the main active component, and effect of preserving agent, which leads to the development of allergic, toxic, or inflammatory processes. Therapeutic regimes implying the appointment of several antihypertensive drugs increases the potential risk of ocular surface pathology.
Palavras-chave
Texto integral
Sobre autores
E. Yani
FSBI "Moscow Scientific Research Institute of Eye Diseases n.a. Helmholtz "Acting Head of the Department of Infectious and Allergic Eye diseases
K. Seliverstova
FSBI "Moscow Scientific Research Institute of Eye Diseases n.a. Helmholtz "
Email: xenia2002@list.ru
Bibliografia
- Quigley H, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br. J. Ophthalmol.2006;90(3):262-67.
- Fechtner R.D., Godfrey D.G., Budenz D., Stewart J.A, Stewart W.C., Jasek M.C. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29(6):618-21.
- Baudouin C., Labb A., Liang H., Pauly A., Brignole-Baudouin F. Preservatives in eyedrops: the good, the bad and the ugly. Progress in Retinal and Eye Research. 2010;29(4): 312-34.
- Алексеев В.Н., Егоров Е.А., Харьковский А.О. Бетаксолол в лечении глаукомы. Клиническая офтальмология 2001;2:(2):58-60.
- Yee R.W. The effect of drop vehicle on the efficacy and side effects of topical glaucoma therapy: a review. Curr. Opin. Ophthalmol. 2007;18(2):134-39.
- Noecker R. Effects of common ophthalmic preservatives on ocular health. Adv. Ther.2001;18(5):205-15.
- Martone G., Frezzotti P., Tosi G.M., et al. An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology. Am. J. Ophthalmol. 2009;147(4):725-35.
- Позднякова В.В., Поздняков В.И., Ибрагимова Д.И., Майчук Ю.Ф. Влияние слезозаместительных глазных капель на сроки эпителизации экспериментальной эрозии роговицы в зависимости от наличия в их составе консерванта. Катарактальная и рефракционная хирургия. 2012; 12(4):36-39.
- Bresson-Dumont H. Ocular intolerance to antiglaucoma medications is underestimated. Bulletin de la Socieеteе belge d'ophtalmologie. 2010;(315):47-53.
Arquivos suplementares
